Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

NCT00283478 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2007-10-31

No results posted yet for this study

Summary

To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.

Conditions

Interventions

DRUG

Iscar Quercus

Sponsors & Collaborators

  • Kentuckiana Cancer Institute

    lead OTHER

Principal Investigators

  • Renato V. LaRocca, MD · Kentuckiana Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283478 on ClinicalTrials.gov